FrancophonIA/ELRC3.0 huggingface dataset:
English: Karvea was originally studied in 11 trials for its effects on blood pressure.
Croatian: Djelovanje lijeka Karvea na krvni tlak izvorno je ispitano u 11 istraživanja.
English: For the full list of all side effects reported with Karvea, see the Package Leaflet.
Croatian: Potpuni popis nuspojava koje su zabilježene s lijekom Karvea potražite u uputi o lijeku.
English: How is Karvea used?
Croatian: Kako se Karvea koristi?
English: How does Karvea work?
Croatian: Kako Karvea djeluje?
English: How has Karvea been studied?
Croatian: Kako je Karvea ispitan?
English: ‘Essential' means that the hypertension has no obvious cause.
Croatian: Karvea se koristi za liječenje esencijalne hipertenzije (visokog krvnog tlaka) u odraslih osoba. „Esencijalna” znači da hipertenzija nema nekog očitog uzroka.
English: If you suddenly notice:
Croatian: Ako iznenada uočite:
English: Availability of resuscitation equipment must be ensured.
Croatian: Potrebno je osigurati dostupnost opreme za oživljavanje.
English: Date of first authorisation: 08/01/2013
Croatian: Datum prvog odobrenja: 08/01/2013
English: Study protocol within 2 months after Commission Decision
Croatian: Plan ispitivanja unutar 2 mjeseca nakon odluke Komisije
English: Number (%) of Subjects Who Met Response Criteria
Croatian: Broj (%) ispitanika koji su ispunili kriterije odgovora
English: Very limited data are available about retreatment after interruption of therapy for more than 4 weeks.
Croatian: Dostupni su vrlo ograničeni podaci o ponovnom liječenju nakon prekida terapije na više od 4 tjedna.
English: Monitoring during treatment
Croatian: Nadzor tijekom liječenja
English: In addition, an updated RMP should be submitted:
Croatian: Nadalje, nadopunjen RMP trebao bi biti dostavljen:
English: Instructions for preparation:
Croatian: Upute za pripremu:
English: The applicant should submit yearly interim reports.
Croatian: Podnositelj zahtjeva treba podnositi godišnja privremena izvješća.
English: No overall differences in safety or efficacy were observed between older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Croatian: Nisu uočene ukupne razlike u sigurnosti ili djelotvornosti između starijih i mlađih bolesnika, ali se ne može isključiti veća osjetljivost nekih starijih pojedinaca.
English: Israel
Croatian: Izrael
English: The data for long-term treatment from controlled clinical studies are limited.
Croatian: Podaci za dugoročno liječenje iz kontroliranih kliničkih ispitivanja su ograničeni.
English: Special attention is recommended for patients with pre-existing cardiopulmonary disease.
Croatian: Preporučuje se posvetiti posebnu pozornost bolesnicima s postojećom kardiopulmonalnim bolestima.
English: Pharmacovigilance Plan or risk minimisation activities
Croatian: Farmakovigilancijski plan ili aktivnosti smanjenja rizika
English: This should be considered when the decision is made for a therapy longer than 6 months.
Croatian: To treba uzeti u obzir kod donošenja odluke o trajanju liječenja dulje od 6 mjeseci.
English: Your doctor may also ask you to wait after your treatment to be sure that you do not have an infusion-related reaction.
Croatian: Vaš liječnik također može od Vas tražiti da pričekate nakon liječenja kako bi bio siguran da nemate reakciju povezanu s infuzijom.
English: Therefore, KRYSTEXXA should not be used during breast-feeding unless the clear benefit to the mother can overcome the unknown risk to the newborn/infant.
Croatian: Stoga se KRYSTEXXA ne smije koristiti tijekom dojenja osim ako očita dobrobit za majku može premašiti nepoznate rizike za novorođenče/dojenče.
English: The potential clinical relevance of these findings is currently unknown; however no adverse effects were associated with the presence of vacuoles.
Croatian: Mogući klinički značaj ovih nalaza trenutno nije poznat; međutim, nuspojave nisu bile povezane s prisutnosti vakuola.
English: Haemolysis and/or Methemoglobinemia
Croatian: Hemoliza i/ili methemoglobinemija
English: Although the 4-week regimen also demonstrated efficacy for the primary endpoint, this regimen was associated with increased frequency of infusion reactions.
Croatian: Iako je 4-tjedni režim liječenja također pokazao djelotvornost za primarnu završnu točku, ovaj režim bio je povezan s povećanom učestalosti infuzijskih reakcija.
English: Therefore, this medicine is not recommended in this age group.
Croatian: Stoga se taj lijek ne preporučuje za ovu dobnu skupinu.
English: KRYSTEXXA is not recommended during pregnancy.
Croatian: KRYSTEXXA se ne preporučuje tijekom trudnoće.
English: The embryofetal development study in rats does not indicate direct or indirect harmful effects with respect to reproductive toxicity.
Croatian: Ispitivanja embriofetalnog razvoja na štakorima ne ukazuju na izravne ili neizravne štetne učinke s obzirom na reproduktivnu toksičnost.
English: You will receive KRYSTEXXA every 2 weeks.
Croatian: Primat ćete lijek KRYSTEXXA svaka dva tjedna.
English: If you have a reaction during the infusion, your doctor may stop or adjust the treatment.
Croatian: Ako ste imali reakciju tijekom infuzije, Vaš liječnik može prekinuti ili prilagoditi Vaše liječenje.
English: The potency of this product should not be compared to the one of another pegylated or non-pegylated protein of the same therapeutic class.
Croatian: Jačina ovog lijeka ne smije se uspoređivati s drugim pegiliranim ili nepegiliranim proteinom iste terapijske klase.
English: Allergic reactions usually happen within 2 hours of the infusion, but may also happen at a later time.
Croatian: Alergijske reakcije obično se događaju unutar 2 sata nakon infuzije ali mogu se dogoditi i kasnije.
English: The MAH shall complete, within the stated timeframe, the following measures:
Croatian: Nositelj odobrenja će, unutar navedenog vremenskog okvira, ispuniti sljedeće mjere: Opis
English: Close monitoring is required during the infusion and for at least 2 hours after the end of the infusion.
Croatian: Potreban je pažljivi nadzor tijekom infuzije i još najmanje 2 sata nakon završetka infuzije.
English: These medicines may put you at higher risk of infusion reaction.
Croatian: Ti lijekovi mogu kod Vas povećati rizik od infuzijske reakcije.
English: • a swelling of the throat, tongue or other part of your body
Croatian: • oticanje grla, jezika ili drugog dijela tijela
English: The optimal treatment duration has not been established (see section 4.4).
Croatian: Optimalno trajanje liječenja nije utvrđeno (vidjeti dio 4.4).
English: This medicine will be stored in a healthcare facility where it is administered.
Croatian: Ovaj lijek se čuva u zdravstvenoj ustanovi gdje se i primjenjuje.
English: 95% Confidence Interval1
Croatian: 95%-tni interval pouzdanosti pvrijednost
English: • If you are allergic to pegloticase, or other uricases or any of the other ingredients of this medicine (listed in section 6).
Croatian: • Ako ste alergični na peglotikazu ili druge urikaze ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: Assessment Time point
Croatian: Vremenska točka procjene
English: Commercial House, Millbank Business Park, Lower Lucan Road, Lucan, Co. Dublin Ireland
Croatian: Commercial House, Millbank Business Park, Lower Lucan Road, Lucan, Co.
English: It is unknown whether the development of anti-PEG antibodies may reduce the efficacy of other PEGylated medicinal products.
Croatian: Nije poznato može li razvoj protutijela na PEG smanjiti djelotvornost drugih PEGiliranih lijekova.
English: Non-clinical studies to evaluate the carcinogenic and mutagenic potential have not been performed.
Croatian: Nisu provedena klinička ispitivanja za procjenu kancerogenog i mutagenog potencijala.
English: Overall Complete Tophus Resolution (Pooled Analysis of GOUT 1 and GOUT 2)
Croatian: Ukupno potpuno otapanje tofa (Skupna analiza ispitivanja GOUT 1 i GOUT 2)
English: KRYSTEXXA in a vial or in an intravenous infusion fluid must never be subjected to artificial heating (e.g., hot water, microwave).
Croatian: KRYSTEXXA u bočici ili u tekućini za intravensku infuziju nikada se ne smije podvrgavati umjetnom zagrijavanju (primjerice, vrućoj vodi, zagrijavanju u mikrovalnoj pećnici).
English: Warnings and precautions Talk to your doctor or nurse before using KRYSTEXXA:
Croatian: Upozorenja i mjere opreza Obratite se svom liječniku ili medicinskoj sestri prije nego primijenite lijek KRYSTEXXA:
English: It is especially important to tell your doctor if you are currently taking other urate-lowering medicines (such as allopurinol or Febuxostat) or medicines containing polyethylene glycol (PEG) (such as pegylated interferon or Doxorubicin).
Croatian: Posebno je važno reći svom liječniku ako trenutno uzimate druge lijekove za sniženje urata (poput alopurinola ili Febuxostata) ili druge lijekove koji sadrže polietilen glikol (PEG) (poput pegiliranog interferona ili doksorubicina).
English: Do not use KRYSTEXXA if you are pregnant or breast-feeding, since it is not known how it will affect you or your baby.
Croatian: Nemojte uzimati lijek KRYSTEXXA ako ste trudni ili ako dojite jer nije poznato kako će to utjecati na Vaše dijete.
English: Take these medicines as directed by your doctor.
Croatian: Uzimajte ove lijekove prema liječničkim uputama.
English: People with gout have too much uric acid in their body.
Croatian: Osobe s gihtom imaju višak mokraćne kiseline u svom tijelu.
English: 4.6 Fertility, Pregnancy and Lactation
Croatian: 4.6 Plodnost, trudnoća i dojenje
English: The results of the on-going reproductive toxicity studies are not available (see section 5.3).
Croatian: Rezultati tekućih ispitivanja reproduktivne toksičnosti nisu dostupni (vidjeti dio 5.3).
English: The average molecular mass of pegloticase is approximately 545 kDa of which the protein moiety constitutes approximately 137 kDa.
Croatian: Prosječna molekularna masa peglotikaze iznosi približno 545 kDa od kojih proteinski dio zauzima približno 137 kDa.
English: In the pregnant rat study there was no evidence of embryotoxicity or teratogenicity at 46 times the clinical exposure (AUC).
Croatian: U ispitivanjima gravidnih ženki štakora nije bilo dokaza embriotoksičnosti ili teratogenosti prilikom izlaganja dozi 46 puta većoj od kliničke izloženosti (AUC).
English: The population PK analyses showed that age, sex and weight did not influence the pharmacokinetics of pegloticase.
Croatian: Farmakokinetičke analize populacije pokazale su da dob, spol i težina ne utječu na farmakokinetiku peglotikaze.
English: Delayed-type hypersensitivity reactions have also been reported.
Croatian: Zabilježene su i reakcije preosjetljivosti kasnog tipa.
English: - if you are currently taking other medicines to lower your uric acid level - if you have been told you have heart failure - if you have ever been told you have an enzyme deficiency that causes anaemia - if you weigh over 100 kg - if you have been treated with KRYSTEXXA before
Croatian: - ako trenutno uzimate druge lijekove za snižavanje razine mokraćne kiseline - ako su Vam rekli da imate zatajenje srca - ako su Vam ikada rekli da imate nedostatak enzima što uzrokuje anemiju - ako ste teži od 100 kg - ako ste prije primali lijek KRYSTEXXA
English: If patients experience treatment-related symptoms affecting their ability to concentrate and react (i.e. headache or dizziness), it is recommended that they do not drive or use machines until the effect subsides.
Croatian: Ako bolesnici osjete simptome povezane s liječenjem koji utječu na njihovu sposobnost koncentracije i reagiranja (primjerice, glavobolja ili vrtoglavica), preporučuje se da ne voze i ne upravljaju strojevima sve dok se učinci ne povuku.
English: Taking into account the PRAC Assessment Report on the PSUR for pegloticase, the scientific conclusions of CHMP are as follows:
Croatian: Uzimajući u obzir PRAC-ovo Izvješće o ocjeni periodičkog izvješća o neškodljivosti (PSUR) za peglotikazu, znanstveni zaključci CHMP-a su sljedeći:
English: The following convention has been used for classification of the adverse reactions reported in the Phase 3 clinical trials (see Table 1 below): very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Croatian: Za klasifikaciju nuspojava zabilježenih u fazi III kliničkih ispitivanja korištena su sljedeća pravila (vidjeti tablicu 1 u nastavku): Vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: The recommended dose of KRYSTEXXA is 8 mg.
Croatian: Preporučena doza lijeka KRYSTEXXA je 8 mg.
English: However, due to variability in the AUC values, AUC proportionality was not seen which might be a reflection of antibody clearance for some of the subjects.
Croatian: Međutim, zbog varijabilnosti u vrijednostima AUC, nije uočena proporcionalnost ovog parametra što bi moglo biti odraz uklanjanja lijeka protutijelima u nekih ispitanika.
English: If haemolysis and/or methemoglobinemia occur in patients receiving KRYSTEXXA, treatment should be immediately and permanently discontinued and appropriate measures initiated.
Croatian: Ako se hemoliza i/ili methemoglobinemija pojave u bolesnika koji primaju lijek KRYSTEXXA, liječenje treba odmah i trajno prekinuti te poduzeti odgovarajuće mjere.
English: For the PEG moiety, urinary excretion is likely to be the major route of elimination.
Croatian: Za PEG dio, izlučivanje mokraćom vjerojatno je glavni način eliminacije.
English: Patients over 100 kg body weight
Croatian: Bolesnici teži od 100 kg
English: If you do not feel well, experience symptoms such as dizziness or headache, or are tired after receiving KRYSTEXXA, you should not drive or operate any machines.
Croatian: Ako se ne osjećate dobro, imate simptome poput vrtoglavice ili glavobolje ili ste umorni nakon primjene lijeka KRYSTEXXA, ne smijete voziti ili upravljati strojevima.
English: Prenatal and postnatal development study in rats, as well as the embryofetal development study in rabbits are ongoing.
Croatian: Prenatalna i postnatalna ispitivanja razvoja na štakorima kao i ispitivanja embriofetalnog razvoja na kunićima još traju.
English: No dose adjustment is needed for patients 65 years of age and older.
Croatian: Prilagodba doze nije potrebna za bolesnika od 65 godina i starije.
English: The PK/PD analysis showed that higher doses were associated with lower uric acid levels and a more rapid decrease in these levels than lower doses.
Croatian: PK/PD analize pokazale su da su više doze povezane s nižim razinama mokraćne kiseline i bržim padom tih razina od nižih doza.
English: • OBLIGATION TO CONDUCT POST-AUTHORISATION MEASURES
Croatian: • Obveze za provođenje mjera nakon davanja odobrenja
English: Week 25
Croatian: Tjedan 25
English: Therefore, in view of available data regarding anaphylaxis and infusion reactions, the Pharmacovigilance Risk Assessment Committee considered that changes to the product information were warranted.
Croatian: Stoga je, u pogledu dostupnih podataka o anafilaksiji i infuzijskim reakcijama, Povjerenstvo za ocjenu rizika na području farmakovigilancije smatralo da su izmjene informacija o lijeku opravdane.
English: There are no data from the use in pregnant women.
Croatian: Nema podataka o primjeni lijeka na trudnicama.
English: • Appropriate aseptic technique should be used when preparing the infusion.
Croatian: • Prilikom pripreme infuzije potrebno je koristiti odgovarajuću aseptičnu tehniku.
English: The long-term risk of prophylactic medications to prevent infusion reactions, such as glucocorticoids, should also be taken into consideration.
Croatian: Potrebno je također uzeti u obzir dugoročni rizik povezan s profilaktičkim lijekovima za sprečavanje infuzijskih reakcija, poput glukokortikoida.
English: It is recommended that patients suspected of receiving an overdose be monitored, and general supportive measures be initiated as no specific antidote has been identified.
Croatian: Preporučuje se nadzor bolesnika za koje se sumnja da su primili prekomjernu dozu te treba započeti s općih suportivnim mjerama jer nije otkriven specifičan antidot.
English: Pharmacotherapeutic group: Anti-gout preparations, other anti-gout preparations, ATC code: M04AX02
Croatian: Farmakoterapijska skupina: Pripravci protiv gihta, drugi pripravci protiv gihta, ATK oznaka: M04AX02
English: What KRYSTEXXA is and what it is used for
Croatian: Što je KRYSTEXXA i za što se koristi
English: KRYSTEXXA can induce severe allergic responses, including anaphylactic shock with cardiac arrest.
Croatian: KRYSTEXXA može uzrokovati teške alergijske odgovore, uključujući anafilaktički šok sa srčanim arestom.
English: The pharmacokinetics of KRYSTEXXA has not been studied in children and adolescents.
Croatian: Farmakokinetika lijeka KRYSTEXXA nije proučavana u djece i adolescenata.
English: M0402: EU Pegloticase post-marketing Observational Study
Croatian: M0402: Opservacijsko ispitivanje peglotikaze nakon stavljanja lijeka u promet na tržištu EU
English: In addition, a further amendment regarding the extension of the time of observation following the end of infusion from 1 hour to 2 hours as a precautionary measure has been included along with a statement that delayed-type hypersensitivity reactions have also been reported.
Croatian: Uz to je uključena dodatna izmjena koja se odnosi na produljenje trajanja nadzora nakon završetka infuzije s 1 sata na 2 sata kao mjere opreza, zajedno s rečenicom da su zabilježene i reakcije preosjetljivosti kasnog tipa.
English: KRYSTEXXA has not been studied in children or adolescents under 18 years of age.
Croatian: KRYSTEXXA nije proučavana u djece ili adolescenata mlađih od 18 godina.
English: All patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) should be screened for G6PD deficiency before starting KRYSTEXXA.
Croatian: Svi bolesnici s većim rizikom od nedostatka G6DP (primjerice, bolesnici afričkog ili mediteranskog podrijetla) trebaju se podvrgnuti probiru na nedostatak G6DP prije početka liječenja lijekom KRYSTEXXA.
English: It is recommended to start this treatment 1 week before initiation of KRYSTEXXA and continue for at least 6 months, unless medically contraindicated or not tolerated.
Croatian: Preporučuje se početi profilaksu tjedan dana prije početka primjene lijeka KRYSTEXXA i nastaviti tijekom najmanje 6 mjeseci osim ako nije medicinski kontraindicirana ili ako ju bolesnik ne podnosi.
English: From a microbiological point of view, the product should be used immediately.
Croatian: S mikrobiološkog stajališta lijek treba upotrijebiti odmah.
English: Also, high titres of anti-pegloticase antibodies and infusion-related reactions showed a tendency to occur in a greater proportion of patients in this weight group (see section 4.8).
Croatian: Također, visoki titri protutijela na peglotikazu i infuzijske reakcije pokazale su tendenciju pojave u većim udjelima u skupini bolesnika s ovom težinom (vidjeti dio 4.8).
English: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but a small number of patients with pre-existing cardiovascular conditions who were treated with pegloticase in the clinical trials had exacerbations of their congestive heart failure.
Croatian: KRYSTEXXA nije službeno ispitivana u bolesnika s kongestivnim zatajenjem srca, ali mali broj bolesnika s prethodnim kardiovaskularnim problemima koji su bili liječeni peglotikazom u kliničkim ispitivanjima imalo je pogoršanja kongestivnog zatajenja srca.
English: Week 13
Croatian: Tjedan 13
English: The Phase 1 pharmacokinetics showed proportionality within the dose interval (0.5 - 8 mg) as reflected in Cmax values.
Croatian: Farmakokinetička ispitivanja faze I pokazala su proporcionalnost unutar intervala doziranja (0,5-8 mg) što se odražavalo i u vrijednostima Cmax.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with KRYSTEXXA in one or more subset of the paediatric population in the treatment and/or prevention of hyperuricaemia related to Tumour Lysis Syndrome (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja lijeka KRYSTEXXA u jednoj ili više podskupina pedijatrijske populacije za liječeneu i/ili prevenciju hiperuricemije povezane sa sindromom lize tumora (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: The safety and efficacy of KRYSTEXXA in children and adolescents aged below 18 years has not been established.
Croatian: Sigurnost i djelotvornost lijeka KRYSTEXXA u djece i adolescenata u dobi mlađoj od 18 godina nije ustanovljena.
English: The first infusion reaction usually occurs after the 2
Croatian: Prva infuzijska reakcija obično se javlja nakon 2. do 4. infuzije.
English: PSURs The PSUR cycle for the medicinal product should follow the standard requirements.
Croatian: PSUR-evi Podnošenje PSUR-a za lijek trebalo bi pratiti standardne zahtjeve.
English: The strength indicates the quantity of the uricase moiety of pegloticase without consideration of the PEGylation.
Croatian: Jačina ukazuje na količinu urikaze u peglotikazi bez uzimanja u obzir PEGilacije.
English: It is unknown whether pegloticase or its metabolites are excreted in human milk.
Croatian: Nije poznato izlučuje li se peglotikaza ili njezini metaboliti u majčino mlijeko.
English: Pegloticase belongs to the class anti-gout medicines.
Croatian: Peglotikaza pripada skupini lijekova protiv gihta.
English: No dose adjustment is needed for patients 65 years of age and older (see section 5.2).
Croatian: Stariji bolesnici Prilagodba doze nije potrebna za bolesnike u dobi od 65 godina i starije (vidjeti dio 5.2).
English: The efficacy and safety of KRYSTEXXA was assessed in two replicate Phase III pivotal trials (GOUT 1 and GOUT 2) that were conducted in 212 adult patients with chronic gout refractory to allopurinol.
Croatian: Djelotvornost i sigurnost lijeka KRYSTEXXA procijenjena je u dva identična pivotalna ispitivanja faze III (GOUT 1 i GOUT 2) koja su provedena na 212 odraslih bolesnika s kroničnim gihtom refraktornim na alopurinol.
English: Anaphylaxis (characterized by stridor, wheezing, peri-oral/lingual oedema, or hemodynamic instability, with or without rash or urticaria) occurred in 14 (5.1%) of 273 total patients treated with KRYSTEXXA in clinical studies.
Croatian: Anafilaksija (karakterizirana stridorom, sipnjom, perioralnim/jezičnim edemom ili hemodinamičkom nestabilnošću s ili bez osipa ili urtikarije) se pojavila u 14 (5,1%) od ukupno 273 bolesnika liječenih lijekom KRYSTEXXA u kliničkim ispitivanjima.
English: Lower response rates were observed in patients over 100 kg BW; however, confounding factors in a small sample size make it unclear if in patients over 100 kg BW the dose was optimal to achieve an effect.
Croatian: Niže stope odgovora uočene su u bolesnika s tjelesnom težinom većom od 100 kg; međutim, zbunjujući čimbenici na malom uzorku čine nejasnim je li doza za bolesnike teže od 100 kg bila odgovarajuća za postizanje učinka.
English: KRYSTEXXA has little or no effect on your ability to drive.
Croatian: KRYSTEXXA utječe malo ili nikako na Vašu sposobnost upravljanja vozilima.
English: What KRYSTEXXA looks like and contents of the pack
Croatian: Kako KRYSTEXXA izgleda i sadržaj pakovanja
English: • If you have a rare blood problem called glucose 6-phosphate dehydrogenase (G6PD) deficiency or favism.
Croatian: • Ako imate rijetki poremećaj zvan nedostatak 6-fosfat dehidrogenaze (G6PD) ili favizam.
English: Bio-Technology General (Israel) Ltd. Be'er Tuvia Industrial Park Kiryat Malachi 83104
Croatian: Be'er Tuvia Industrial Park Kiryat Malachi 83104
English: From a bacteriological point of view, the product should be used immediately.
Croatian: S bakteriološkoj stajališta lijek treba upotrijebiti odmah.
English: Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolysis and methemoglobinemia.
Croatian: Nedostatak glukoza-6-fosfat dehidrogenaze (G6DP) i drugi poremećaji staničnog metabolizma za koje se zna da uzrokuju hemolizu i methemoglobinemiju.